drugset / Trial / NCT00606866
MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to determine maximum tumor shrinkage, time to progression, survival, drug concentration, and degree of skin toxicity.
Timeline
- Start
- 2004-07
- Primary completion
- 2007-01
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sorafenib | Small molecule | 200 mg | — |
| Comparator | Sorafenib | Small molecule | 400 mg | — |